NCT05028829View on ClinicalTrials.gov

Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

March 1, 2031

Conditions
Liver FibrosesCirrhosis
Interventions
DRUG

Atorvastatin 20mg

Oral administration of atorvastatin 20 mg

DRUG

Placebo

Oral administration of placebo

Trial Locations (2)

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

University of Texas Southwestern Medical Center

OTHER

lead

Raymond Chung

OTHER